PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “VIRAL VACCINES”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMedDate not supplied

[Endotoxic contamination of biological products (ribosomal vaccines, viral vaccines and interferon)].

The A.A. have examined by the Limulus assay the possible endotoxin contamination in some biological products (ribosomal vaccines, viral vaccines, interferon). While the preparations of influenza vaccines and a partially purified fraction of ribosomal vaccine from Pseudomonas aeruginosa exhibit a gelation of lysate with high levels of endotoxin, rubeola vaccines, interferon and a purified fraction of ribosomal vaccine, presented a negligible amount of endotoxin. The results are discussed with the aim to examine the possible role of contaminating endotoxin in the mediation of some adverse effects and of the unsuspected extrinsic adjuvant activities developed in clinical and experimental use of these preparations.

Bacterial Vaccines↗
PubMed1986

Early interactions between animal viruses and the host cell: relevance to viral vaccines.

Viral recognition of specific receptors in the host cell plasma membrane is the first step in virus infection. Attachment is followed by a redistribution or capping of virus particles on the cell surface which may play a role in the uptake process. Certain viruses penetrate the plasma membrane directly but many, both enveloped and non-enveloped viruses, are endocytosed at coated pits and subsequently pass into endosomes. The low pH environment of the endosome facilitates passage of the viral genome into the cytoplasm. For some viruses the mechanism of membrane penetration is now known to be linked to a pH-mediated conformational change in external virion proteins. As a consequence of infection there are alterations in the permeability of the plasma membrane which may contribute to cellular damage. Recent advances in the understanding of these processes are reviewed and their relevance to the development of new strategies for vaccines emphasised.

Adenoviridae↗
PubMed2004

A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.

Viral vaccines could be considered among the most important medical achievements of the 20th century. They have prevented much suffering and saved many lives. Although some curative antiviral drugs exist, we desperately depend on efforts by academic, governmental and industrial scientists in the advancement of viral vaccines in the prevention and control of infectious diseases. In the next decade, we hope to see advancement in the development of current and investigational viral vaccines against childhood and adult infections. In this article, we will review the licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.

Adolescent↗
PubMed2003

Comparison of a multivalent viral vaccine program versus a univalent viral vaccine program on animal health, feedlot performance, and carcass characteristics of feedlot calves.

A field study was conducted under commercial feedlot conditions at 2 sites in western Canada to determine the relative effects of a univalent viral vaccine (MLV 1) program versus a multivalent viral vaccine (MLV 4) program on animal health; feedlot performance; and carcass characteristic variables of fall-placed, auction market derived, feedlot calves. Five thousand one hundred and sixty-three calves were processed and randomly allocated to 1 of 2 experimental groups as follows: MLV 1, which received a modified live infectious bovine rhinotracheitis (IBR) virus vaccine upon arrival at the feedlot and again at approximately 70 days on feed (DOF); or MLV 4, which received a modified live IBR virus, parainfluenza-3 virus, bovine viral diarrhea virus, and bovine respiratory syncytial virus vaccine upon arrival at the feedlot and again at approximately 70 DOF. A total of 20 pens (10 pens at the site located near High River, Alberta and 10 pens at the site located near Vegreville, Alberta) were allocated to the study. On both a live and carcass weight basis, final weight, weight gain, and average daily gain (ADG) were significantly (P < 0.05) improved in the MLV 4 group as compared with the MLV 1 group. However, there were no significant (P > or = 0.05) differences in DOF, daily dry matter intake, dry matter intake to gain ratio (DM:G) live, or DM:G carcass between the experimental groups. In addition, there were no significant (P > or = 0.05) differences between the experimental groups in any of the carcass characteristic variables measured. The initial undifferentiated fever (UF) treatment rate was significantly (P < 0.05) lower in the MLV 4 group as compared with the MLV 1 group. There were no significant (P > or = 0.05) differences in the other measures of health between the experimental groups. In the economic analysis, there was a net advantage of $0.74 CDN per animal in the MLV 4 group as compared with the MLV 1 group due to lower initial UF treatment and improved ADG, even though the cost of the vaccine program was higher in the MLV 4 group.

Alberta↗
PubMed1995

Antibody responses by cattle after vaccination with commercial viral vaccines containing bovine herpesvirus-1, bovine viral diarrhea virus, parainfluenza-3 virus, and bovine respiratory syncytial virus immunogens and subsequent revaccination at day 140.

Calves were vaccinated with four different commercial viral vaccines containing bovine herpesvirus-1 (BHV-1), bovine viral diarrhea (BVDV), parainfluenza-3 virus (PI-3V), and bovine respiratory syncytial virus (BRSV) immunogens. For the initial vaccination certain vaccines were given twice (days 0 and 28), whereas other vaccines were given on day 0. The calves received another injection on day 140 with the vaccine originally given on day 0. The sera were collected at days 0, 7, 14, 21, 28, 42, 56, 84, 112, 140, 154, 168, and 196 and assayed for viral neutralizing antibodies. The calves were seronegative to BHV-1, BVDV, and BRSV at the onset of the experiment; however, the calves were PI-3V antibody positive due to prior active infection. The commercial vaccines were: (I) inactivated; (II) modified live virus (MLV); (III) combination of chemically altered live virus, MLV, and inactivated virus; and (IV) combination of inactivated and MLV. Among the vaccine groups there were differences in onset and duration of antibodies as measured by geometric mean titers to each immunogen in postvaccination collection dates compared to day 0 titers; and likewise compared to day 140 titers after revaccination at day 140. There were also differences in antibody titers to the various viruses among the vaccine groups on specific collection dates. All four vaccines induced increased BHV-1 antibodies by day 14 after the initial injection. The antibody titers induced by MLV BHV-1 and the chemically altered BHV-1 vaccines had greater duration than those induced by the inactivated vaccine.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed2003

[New perspectives in viral vaccines].

New viral vaccines, based on molecular research into genomes and proteins, should come into routine use in the coming decades. At the same time, use of different immunizing antigens within a single dose is also expected to grow more common, with the purpose of reducing the number of vaccinations administered to target populations. Given Brazil's scientific and technological importance, the country should enhance its participation in the development of new vaccines and in the evaluation of their efficacy by involving a larger number of researchers and technologists and boosting investment in these activities.

Brazil↗
PubMed1991

Bovine viral diarrhea virus contamination of nutrient serum, cell cultures and viral vaccines.

Bovine viral diarrhea virus (BVDV) infection is common in the bovine population. Infection in utero leads to virus and antibody contamination of the fetal bovine serum used in cell cultures. These contaminants can interfere with diagnosis of viral infection. The high frequency of virus and antibody detection in individual animal or small pool samples suggests that any large pool of unscreened sera will be contaminated. Infection of cell cultures with BVDV can lead to interference with the growth of other viruses. Vaccine produced on contaminated cells may in turn be contaminated, leading to seroconversion or disease in the vaccine. The safety, purity, and efficacy of viral vaccines require BVDV testing of ingredients, cell substrates and final product. Methods for detection of BVDV in nutrient serum, cell cultures, seed viruses, and viral vaccines, and the frequency of their detection at the National Veterinary Services Laboratories are discussed.

Animals↗
PubMed1995

[Immunity to measles, mumps and rubella in children vaccinated with triple viral vaccine].

OBJECTIVE: To check up on measles-mumps-rubella immunity in children vaccinated with MMR vaccine. DESIGN: A descriptive cross-sectional study trough seroepidemiological survey. SETTING: Oliver-Miralbueno Health Centre, Zaragoza. PATIENTS: 92 healthy children of 5, 7 and 9 years of age who went for clinical preventive services. All of them vaccinated with MMR at the age of 15 to 18 months. None of them had suffered from measles, mumps or rubella. MEASUREMENTS AND MAIN RESULTS: 1) The percentage of seronegative children (title less than 1:8) was: 9.8% for measles, 8.7% for rubella, and 27.2% for mumps. 2) As to the time differences among seropositive and seronegative children. CONCLUSIONS: The study reveals that there is a high percentage of MMR vaccinated children showing minimal or undetectable levels of antibodies.

Age Factors↗
PubMed1998

Adjuvants and delivery systems for viral vaccines--mechanisms and potential.

Of the vaccines against viral diseases of man currently available, several are less than satisfactory, and the present surge of interest in improving such vaccines, and in developing new vaccines against viral diseases as yet unchallenged, has led to major developments in three areas. The capacity to identify the nature and form of antigenic epitopes in proteins allows the specific design of molecular entities to promote relevant and protective immune responses. Such entities, although ideal in terms of specificity and purity, may not achieve their goals through failure to reach relevant cells of the immune system due to simple dilution, elimination by host enzymes or lack of specific targeting. Concomitant with the above there has been development of a plethora of adjuvants aimed at enhancing immune responses to these 'new' immunogens, paralleled by an almost equally rapid increase in understanding the complex nature of the immune response, particularly with respect to antigen processing, the nature and role of cytokines and the importance of T-cell subsets in infection. These developments allow exploration of matching the properties and mechanistic action of a given adjuvant to a defined immune response. Adjuvants can be grouped according to their physical characteristics and mode of action. They include particulate adjuvants, oil and emulsifier-based adjuvants, those providing controlled antigen delivery, adjuvants based on specific targeting of antigen, and gel-type adjuvants. They may act non-specifically in promoting an immune response to an antigen through depot formation, or very specifically as in a "delivery system" where an antigen is linked to a cellular protein, targeted to a specific cell receptor. As adjuvant technology develops it is becoming increasingly clear that these differing approaches may be combined, and an adjuvant/delivery system designed, to provide slow release of a targeted antigen. The role of adjuvants in modern viral vaccine technology and their influence on the immune system are the subject of this review.

Adjuvants, Immunologic↗
PubMed1989

The effects of vaccination with tissue culture-derived viral vaccines on detection of antibodies to equine arteritis virus by enzyme-linked immunosorbent assay (ELISA).

An enzyme-linked immunosorbent assay (ELISA) was developed for the detection of serum antibodies to equine arteritis virus (EAV). Results from this assay produced a good correlation with results from virus neutralisation tests in horses which had not been regularly vaccinated with commercially available mammalian tissue culture-derived viral vaccines. Vaccination of some horses with tissue culture-derived vaccines induced the formation of antibodies to bovine serum. These antibodies reacted with the bovine protein contaminants in the EAV ELISA antigen, producing false-positive results. Non-viral protein contaminants were found to be closely associated with EAV in that they co-purified with the virus during gradient centrifugation.

Animals↗